A Systematic Review on COVID-19 Vaccine preferences using Discrete Choice Experiments

Adidja AMANI ^{a,b}, Helen KAMO SELENGUAI ^c, Yolande DJIKE PUEPI ^d, Iyale Astadjam DAIROU ^c, Sebastien KENMOE ^{d, e}, Ariane NOUKO ^f, CHEUYEM LEKEUMO Fabrice Zobel ^b, Suzanne SAP NGO UM ^b, Paul Olivier KOKI NDOMBO ^b, Wilfried MBACHAM ^b, Pierre ONGOLO-ZOGO ^b

^a Ministry of Public Health, Yaounde, Cameroon.

^b Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon.

^c Faculty of Science, University of Ngaoundere, Ngaoundere, Cameroon.

^d Faculty of Science, University of Buea, Buea, Cameroon.

^eCentre Pasteur of Cameroon, Yaounde, Cameroon.

^fClinical Research Education Networking & Consultancy, Douala, Cameroon.

Corresponding author : Adidja Amani (Email: amaniadidjamd@gmail.com).

Abstract

Objective: To determine the attributes of COVID-19 vaccines that influence vaccine acceptance using a DCE through a systematic review.

Methods: A systematic search was carried out for articles published up to November 2021 in the PubMed, Psycinfo, Embase, Web of Science, and Global Index Medicus databases. The electronic search algorithm consisted of the terms (Covid-19) AND (Vaccine) AND (discrete choice experiment).

Findings: A total of 39 records were retrieved of which 18 duplicates were identified and removed. Of the remaining 21 records, 10 were excluded because they did not use a DCE approach. 11 studies were included in the meta-analyses with a total of 42 795 participants from **NOTE**: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. three WHO regions. We examined 13 attributes of COVID-19 vaccine that influenced

acceptance; cost, vaccine efficacy, number of doses, risk of side effects, proof of vaccination, vaccination setting, duration of immunity, doctor's recommendation, proportion of acquaintances vaccinated, region of vaccine manufacture, background knowledge of herd immunity, life attenuated or mRNA, speed of vaccination development. The four attributes reported to influence COVID-19 vaccine preferences most worldwide were; high vaccine efficacy, low risk of side effects, long duration of immunity and low number of doses of the vaccine.

Conclusion: The most preferred COVID-19 vaccine attributes should be taken into account by vaccine manufacturers and public health policy makers for better introduction and acceptance of COVID-19 vaccine to the world.

Keywords: COVID-19, Vaccine preferences, Discrete Choice Experiment.

Introduction

Coronavirus Disease 2019 (COVID-19) is a pneumonia, caused by a newly identified coronavirus now called Severe acute respiratory syndrome (SARS)-CoV-2 [1]. As of 15 November 2021, SARS-CoV-2 has infected more than 250 million people and caused the deaths of more than 5 million people worldwide, resulting in a case-fatality rate of about 2.1% [2]. Currently, there is no effective treatment for the disease, and the relaxation of non-medical interventions such as the widespread use of face masks, social distancing and home confinement often leads to a re increase in the number of cases [3]. More than a year after the WHO declared COVID-19 a pandemic, it continues to impose a heavy burden on public health systems and affects populations with a negative impact on economies worldwide [4, 5]. Thus, only a vaccine seems to be the right solution to this problem as vaccines are considered the most effective way to control infectious diseases. Since January 2021, several vaccines with efficacy rates of up to

90% have been developed by major laboratories, licensed by the WHO and put on the market to stop the spread of the COVID-19 pandemic [6, 7].

However, the long-term success of the vaccine response to the COVID-19 pandemic will depend on herd immunity, as bringing these vaccines to market is only half the challenge [8]. Thus, herd immunity can be achieved through natural means, stop-and-go strategies, or mass vaccination of the population [9]. However, the path to bringing a new vaccine to market can be politically and economically complicated and COVID-19 vaccines are no exception [10]. In addition, the ideas and opinions of different stakeholders, such as policy makers and health professionals, may affect the uptake of the vaccine to some extent by the general public and may lead to vaccine hesitancy, a major barrier to achieving herd immunity [11].

Vaccine hesitancy can be explained by several factors, including misinformation [1, 12], vaccine novelty and safety, side effects, efficacy, duration of protection, cost, number of doses, route of transmission, location of vaccination sites, disease burden, emergency use authorization, or politicized approval of the vaccination schedule, and this hesitancy may vary considerably from country to country and with the emergence of new SARS-CoV-2 variants [1, 6, 7, 9].

Heterogeneity factors (age, education and financial income) in inter-individual vaccine preferences may have an impact on vaccination [7]. Therefore, there is an urgent need to find out the hindrances to vaccine uptake, which is the most critical factor for the successful adoption of any vaccination program [1]. Understanding the factors that motivate vaccine hesitancy against COVID-19 will highlight targets for public health communication programs that can increase vaccine acceptance.

Although opinion polls have highlighted the issue of COVID-19 vaccine hesitancy, they have been of limited use in preparing mass vaccination campaigns [9]. In contrast, discrete

choice experiments (DCEs) have proven to be robust methods for estimating behavior and preference prediction in health economics [13]. These methods allow for accurate estimation of strict refusal and acceptance of vaccination for a range of proposed realistic scenarios [14].

We therefore synthesized data from the DCE literature to highlight the attributes of COVID-19 vaccines that influence vaccine preferences and lead to vaccine hesitancy in order to help public health authorities better introduce COVID-19 vaccination to the general public to achieve herd immunity and stop the pandemic.

Methods

Study design and eligibility criteria

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) approach served as template for this review [15]. The review was declared in the International Prospective Register of Systematic Reviews under number CRD42021265688. All types of published studies evaluating the preferences of Covid-19 vaccine using a discrete choice experiment approach were of interest for this review. Studies from all geographic regions were selected. Review articles were excluded.

Data sources and search strategy

A systematic search was carried out for articles in English and French published up to November 2021 in the PubMed, Psycinfo, Embase, Web of Science, and Global Index Medicus databases. The electronic search algorithm consisted of the terms that cover (Covid-19) AND (Vaccine) AND (discrete choice experiment). Additional studies were also searched from the reference list of relevant studies.

Data extraction and synthesis

Duplicate studies from the article search were removed and the remaining articles selected based on a brief overview of the article's abstract and title. Isolated relevant articles were independently assessed for eligibility and the data extracted by two investigators independently (AA and SK). The information collected covered the first author's name, year of publication, geographical location, ethnicity, period of the study, participants characteristics (mean age, SD), the total number of study participants, number of adults willing to be vaccinated, inclusion criteria of participants of each study, and the attributes of the vaccine against Covid-19 which influences the acceptance of the vaccine. Discussion and consensus were reached among authors regarding article selection and data extraction.

Assessment of study quality

A critical appraisal of the quality of the studies included was carried out following the 10 questions for risk of bias assessment as described by Hoy et al. Possible answers to the questions were "yes", "no", "unclear" and "not applicable" due to the content of the articles. For all "yes" answers, a score of 1 was assigned and 0 for the others. Articles were considered to be at high, moderate, and low risk of bias when the total score was 0–3, 4–6, and 7–10 respectively. All disagreements were resolved by discussion and consensus between authors.

Results

Results of Study Search

A total number of 39 records were identified and 18 duplicates removed (Figure 1). Of the remaining 21 records, 10 were excluded because there were not DCE approach, COVID-19 vaccine or study protocol. This is how for the qualitative review, we conserved 11 records [1, 4, 7, 9, 11, 13, 16, 18, 19, 20, 22].



Figure 1 : Forest diagram of the study

Main findings

Table I summarizes the main characteristics of all studies included in the review and Table II summarizes the attributes investigated in DCE per study and the main findings.

The first study retained in our systematic review, used DCE to compare COVID-19 vaccine hesitancy between participants from China and those from America with 5375 and 3702 respondents respectively. For respondents in China; cost of vaccines was the first factor of hesitancy followed by efficacy of the vaccine and adverse effects of the vaccine. While for the American counterparts; efficacy of the vaccine was the first factor followed by the cost of the vaccine. It was also reported that in China; only 82% of study population accepted to be vaccinated, 31.9% of them followed recommendation by a doctor. While in the US; 72.2% of study population accepted to be vaccinated, 50.2% of them following a doctor's recommendation, 59.4% following advice from friends and family and 64.8% did so freely. China respondents preferred an inactivated vaccine while their American counterparts preferred mRNA vaccine. [1]

The second included article in our qualitative review appraised COVID-19 vaccination preferences in the United States using DCE in 1153 adult participants. They studied the effect of the following attributes on vaccination acceptance; proof of vaccination, vaccination setting, vaccine effectiveness, duration of immunity and risk of severe side effects. Its main findings; less educated people were more likely to be unwilling to take the vaccine (p < 0.001), among those willing, vaccine uptake on the DCE ranged from 61.7-97.75% depending on the vaccine attributes. Vaccine effectiveness and safety was the factor with largest effect. They also reported that offering proof of vaccination and choice of setting for vaccination significantly increased uptake. Duration of immunity had the least influence on vaccine acceptance. [4]

The third study accessed individual preferences for COVID-19 vaccination using DCE in 1883 participants from 6 provinces in China selected by stratifies random sampling methods. The following seven vaccine attributes were used, effectiveness, side effects, accessibility, number of doses, vaccination sites, duration of vaccine protection, proportion of acquaintances vaccinated. They reported that out of the seven, those with highest probability of vaccination were; vaccine effectiveness, risk of serious side effects, small vaccination fee, fewer doses, larger the protection duration, higher proportion of acquaintances vaccinated. They also reported that individuals who were older, lower level of education, lower income, higher trust in vaccine, higher perceived risk of infection displayed a higher probability to be vaccinated. [7]

The fourth study worked on COVID-19 vaccine hesitancy in population in France using DCE, 1942 participants were included out of which 560 refused the vaccine scenario in the DCE. This study examined the following attributes; vaccine efficacy (50%, 80%, 90%, 100%), risk of serious side effects (1 in 10 000, 1 in 100 000), region of vaccine manufacturer (EU, China, USA), place of vaccination (vaccination centre, pharmacy, doctor's office), background information about herd immunity (no information, information), doctor's advice on vaccination (no opinion, recommended). Outright refusal and vaccine hesitancy was associated with the female gender, age, lower level of education, poor compliance with vaccines in the past, no report of any chronic disease. Outright refusal was associated with lower perceived severity of COVID-19. Vaccine hesitancy was lower when herd immunity benefits were communicated, hesitancy increased for vaccines produced in China with 50% efficacy and 1/10 000 risk of serious side effects. [9]

The fifth study studied public preferences for COVID-19 vaccines in China using DCE. They had 1236 participants, they study the following attributes; effectiveness (50%, 90%), protection duration (6 months or 18 months), adverse effects (1-2days, none), frequency of injection (3 or 2), price (200 CNY or 0), place of origin (imported or domestic). The public preferences in order of highest acceptance; higher effectiveness of vaccine, long protective duration, very few adverse events, being manufactured overseas. It was noted that vaccine price was the least on the list. [11]

The sixth study was done in the UK; they used online DCE to explore preferences of COVID-19 vaccines in 1501 participants. The attributes studied were; level of protection offered (50%, 70%, 90%), recommender of the vaccine (general practitioner (GP), National Health Service (NHS)), number of doses needed for full protection (one or two doses), location in which the vaccine is administered (local GP's office or mobile vaccination unit), coverage in the media (positive coverage on newspapers, television, radio or positive coverage on WhatsApp, blogs, social media). They outlined that efficacy was the factor that most influenced vaccine selection; 90% efficacy preferred 2.8 times more than 70%, and this was more pronounced in individuals above 55 years of age. For the other attributes; one dose was preferred to 2 doses, recommendation from GP preferred to that of NHS, vaccination at the GP's office was preferred to that on social media. [13]

The seventh study accessed if COVID-19 vaccine lived up to the American expectations in 5940 participants, they accessed six attributes in the DCE; country of origin (US, UK, China and Russia), effectiveness (50%,70%, 90%), risk of minor side effects (1 in 2, 1 in 10, 1 in 100), dose required (1 or 2), vaccine type (mRNA or weakened virus), months spent in development (9months, 12 months, 15 months). They found out that the three main factors for vaccine acceptance were the following in order; US made vaccine, followed by a vaccine with 90% effectiveness, and less than 1% risk of minor side effects. [16]

The eighth study worked on quantifying healthcare and welfare sector workers' preferences around COVID-19 vaccination using DCE in 4346 participants in France. They reported high vaccine efficacy (at least 50%) and mRNA vaccine preferred to live attenuated vaccine [18].

The ninth study was on preferences for COVID-19 vaccine distribution strategies in US using DCE with 2895 participants. Single dose vaccination was preferred to two dose vaccination, vaccination once was preferred to annual vaccination or additional vaccination with boosters, reducing waiting time at vaccination sites was also an important factor. They also reported four distinct preference phenotypes; vaccine features, vaccine service delivery, social proof of vaccine safety and indifference to vaccine service delivery [19].

The tenth study examined COVID-19 coverage, concerns, and preferences among Chinese ICU clinicians using DCE. They had 11 951 participants and reported vaccine hesitancy among ICU clinicians was due to speed of vaccination development and adverse reactions [20].

The last study examined if COVID-19 vaccination willingness increase, if mobile technologies prohibit unvaccinated individuals from public spaces using DCE in 873 participants in China. They reported that willingness to vaccine appears to increase if mobile technology prohibits unvaccinated individuals from public spaces and public transportation [22].

Study		Study year and country	Study sample Size and study	Study Objective	Study design, selection criteria and	Statistical analysis
1.	Lui et al	2020 China and United States	population 9077 participants General population	Investigate the differences in vaccine hesitancy and preference of the COVID-19 vaccines between China and US.	A cross-national online survey using discrete choice experiments	A propensity score matching (PSM) was performed to enable a direct comparison between the two countries
2.	Craig et al	2020 United States	1153 participants General population	To compare persons willing and unwilling to be vaccinated against COVID-19 and to estimate the effects of vaccination attributes on uptake.	A cross-national online survey using discrete choice experiments	An opt-out inflated logit model was estimated to test for respondent differences and attribute effects.
3.	Leng et al	2020 China	1883 participants General population	To determine individual preferences for COVID-19 vaccinations in China, and to assess the factors influencing vaccination decision- making to facilitate vaccination coverage.	A D-efficient Discrete Choice online Experiment was conducted by stratified random sampling method	Forty-eight hypothetical two alternative choice tasks were created in STATA 15.0
4.	Schwarzinger et al	2020 France	1942 participants Working age group with no history of COVID-19	To assess the effects of vaccine characteristics, information on herd immunity and general practitioner recommendation on vaccine hesitancy.	Cross-sectional online survey using DCE; Randomly selection; stratified by gender, age, education, household size, region and area of residence.	A single-hurdle repeated discrete choice model
5.	Dong et al	2020 China	1236 participants General population	To examine how factors related to vaccine characteristics, their social normative influence and convenience of vaccination can affect the public's preference for the uptake of the COVID-19 vaccine in China.	Cross- sectional online survey Random selection	A mixed logit regression model was used to analyze the DCE data
6.	McPhedran et al	2021 United Kingdom	1501 participants General population	To enhance and design the implementation of the	Cross- sectional online survey Random selection	Hybrid logit models and opt- outs in R statistical software

Table I: General characteristics of studies included in review

				COVID-19		
 7.	Motta et al	2021 United States of America	5940 participants General population	vaccination program. Assess how properties of vaccines themselves might influence vaccination intentions.	Cross- sectional online survey Random selection	Expectations tested using a conjoint experimental design
8.	Luévano et al	2021 France	4346 participants Healthcare and welfare workers	To analyze preferences around promotion of COVID-19 vaccination among workers in the healthcare and welfare sector	Cross- sectional online survey Random selection	Single profile DCE NGENE software (Choice metrics) used for statistical analysis.
9.	Eshun- Wilson et al	2021 United States	2895 participants General population	To inform COVID-19 vaccine distribution strategies that are aligned with public preferences	Cross- sectional online survey Random selection	Mixed logit models were used to generate mean utilities for the population and standard deviations of the random coefficients.
10.	Huang et al	2021 China	11951 participants ICU clinicians	To understand the reasons behind vaccination refusal, and assess preferences for COVID-19 vaccines among Chinese ICU clinicians.	Cross- sectional online survey Random selection	
11.	Wang et al	2021 China	873 participants General population	Examined the effects of a "Health Code"- based vaccine mandate on willingness to vaccinate for COVID-19 in China.	Cross- sectional online survey Random selection	A d-efficient design matrix with 36 different choice sets within 12 blocks was produced with NGENE (ChoiceMetrics, 2014)

$\label{eq:table_transform} \textbf{Table II}: \ \text{vaccine attributes studied and findings}$

	Study	Vaccine Attributes investigated	Main findings
1	Lui at cl		For recommendants in Chines and of
1.	Lui et al	Cost,	For respondents in China; cost of
		Efficacy.	followed by efficiency of the vaccine and
			adverse effects of the vaccine
			A mariage acounterparts: office and of the
			American counterparts, efficacy of the
			the cost of the vaccine
2	Craig et al	Proof of vaccination	Vaccine effectiveness and safety was the
2.	chung of un	Vaccination setting	factor with largest effect
		Vaccine effectiveness	
		Duration of immunity	
		Risk of severe side effects.	
3.	Leng et al	Effectiveness,	Order of vaccine preferences were;
	C	Side effects,	vaccine effectiveness, risk of serious side
		Accessibility,	effects, small vaccination fee, fewer
		Number of doses,	doses, larger the protection duration,
		Vaccination sites,	higher proportion of acquaintances
		Duration of vaccine	vaccinated.
		protection,	
		Proportion of acquaintances	
		vaccinated.	
4.	Schwarzinger	Vaccine efficacy,	Outright refusal was associated with
	et al	Risk of serious side effects,	lower perceived severity of COVID-19.
		Region of vaccine	Vaccine hesitancy was lower when herd
		manufacturer,	immunity benefits were communicated.
		Place of vaccination,	Hesitancy increased for vaccines
		Background information	produced in China with 50% efficacy and
		about herd immunity,	1/10 000.
		Doctor's advice on	
		vaccination.	
5.	Dong et al	Effectiveness (50%, 90%),	The public preferences in order of highest
		Protection duration (6 months	acceptance; higher effectiveness of
		or 18 months),	vaccine, long protective duration, very
		Adverse effects (1-2days,	few adverse events, being manufactured
		none),	overseas.
		Frequency of injection,	
		Price,	
		Place of origin.	
6.	McPhedran et	Level of protection offered,	They outlined that efficacy was the factor
	al	Recommender of the vaccine,	that most influenced vaccine selection;
		Number of doses needed for	90% efficacy preferred 2.8 times more
		full protection,	than 70%, and this was more pronounced
		Location in which the vaccine	in individuals above 55 years of age.
		is administered,	
		Coverage in the media.	

7	Motta et al	Country of origin	They three main factors for vaccine
7.	Wotta et al	Effectiveness	accordance ware the following in order
		Dials of minor oids offerete	LS made massing fallowed by a massing
		Risk of minor side effects,	US made vaccine, followed by a vaccine
		Dose required,	with 90% effectiveness, and less than 1%
		Vaccine type,	risk of minor side effects
		Months spent in development.	
8.	Luévano et al	Vaccine efficacy,	They reported high vaccine efficacy (at
		Indirect protection,	least 50%) and mRNA vaccine preferred
		Vaccine safety,	to live attenuated vaccine
		Protection duration,	
		Recommendation/incentive.	
9.	Eshun-Wilson	Vaccination location,	Single dose vaccination was preferred to
	et al	Waiting time at vaccination	two dose vaccination, vaccination once
		site,	was preferred to annual vaccination or
		Number of doses required,	additional vaccination with boosters,
		Vaccination enforcement,	reducing waiting time at vaccination sites
		Who has already received	was also an important factor.
		vaccine in community,	-
		Vaccine frequency.	
10.	Huang et al	Effectiveness	Vaccine hesitancy among ICU clinicians
		Speed of vaccination	was due to speed of vaccination
		development	development and adverse reactions
		Adverse effects	
11.	Wang et al	Price,	Willingness to get vaccinated appears to
		Origin of vaccine,	increase if mobile technology prohibits
		Probability of fever as side	unvaccinated individuals from public
		effect,	spaces.
		Effectiveness,	-
		Location of vaccination,	
		Number of doses,	

Discussion

The review analysed information from eleven studies from three WHO regions; America (USA), West Pacific (China) and Europe (France and United Kingdom) and four countries; United States of America (3 studies), China (5 studies), United Kingdom (1 study), and France (2 studies). A total of 42, 795 participants from the eleven studies were included in our review. A total of thirteen factors were examined in the DCE from all studies reviewed; cost, vaccine efficacy, number of doses, risk of side effects, proof of vaccination, vaccination setting, duration of immunity provided by the vaccine, doctor's recommendation, proportion of acquaintances vaccinated, region of vaccine manufacture, background knowledge of herd

immunity, if vaccine is life attenuated or mRNA, speed of vaccine development. The main finding of our review is out of the thirteen factors examined in all the studies, there are four factors that were seen to have more influence on COVID-19 preferences than the others; high vaccine efficacy, low risk of side effects, long duration of immunity of the vaccine and reduced number of doses of the vaccine. In addition to these four main preferences mentioned above, participants from China were also concerned about vaccine cost; those from United Kingdom and France were particular on region of vaccine manufacture they preferred vaccines produced in Europe. A peculiarity of participants from the United Kingdom was they preferred receiving the vaccine in a doctor's office or hospital setting rather than in a mobile vaccination unit. Participants from America also preferred vaccine manufactured in their country in addition to the four main factors for COVID-19 preferences mentioned above.

As seen in Tables 1 and 2; all the studies included in the review using the DCE showing the quality of the review. All the studies used a cross sectional online survey for data collection, with average sample size of 3891participants [873; 11951], nine out of eleven of the studies targeted the general population while two studies targets health care workers, welfare workers and ICU physicians. Selection criteria of participants in all of the studies were randomised sampling method. Statistical methods used in analysis of results mixed and hybrid logit models, opt-out models, propensity score matching in R and Stata. All the studies clearly brought out the vaccine attributes they were investigating in the DCE; on average each study investigated 5 vaccine attributes [2; 7].

Our findings are similar to that reported in systematic review using DCE on parent, provider and vaccine preferences for Human Papilloma vaccine (HPV) which reported high vaccine effectiveness as the attribute that influenced acceptance most. They also reported age of vaccination and cost of vaccine as main preferences for vaccine acceptance[23]. Another systematic review on individual preferences for child and adolescent vaccine attributes reported

low risk of side effects, duration of protection and vaccine cost as the most preferred attributes of vaccine. They worked on childhood vaccines, Human Papilloma Vaccine, meningococcal vaccine, Hepatitis B vaccine, diphtheria, tetanus vaccine [24]. A systematic review on choice based experiments on vaccine preferences driving vaccine decision making of different target groups reported vaccine effectiveness, vaccine risk, cost and protection duration as the main factors influencing vaccine decision (Diks et al., 2021). These three systematic reviews have findings similar to our findings although they studied preferences for vaccines other than COVID-19 vaccine; high vaccine effectiveness, low risk of side effects and duration of vaccine protection are reported in all three studies as factors influencing preferences.

On the other hand, a systematic review on effectiveness and acceptability of parental financial incentives and quasi mandatory schemes for increasing uptake of vaccination in preschool children reported that universal parental financial incentives were preferred to quasi-mandatory interventions [26]. Another systematic review on acceptability of parental financial incentives and quasi-mandatory interventions for preschool vaccination reported that incentives and quasi-mandatory vaccination could be effective particularly in disadvantaged groups but were not considered appropriate motivation for vaccination in children [27]. Our study did not examine incentives and quasi-mandatory aspects of COVID-19 vaccination.

The implication of this review for research is that more studies need to be done using DCE in other WHO regions like Africa, Eastern Mediterranean, and South-East Asia in order to know COVID-19 preferences to inform vaccine manufacturers and public health decision makers.

The results from this review should be taken into consideration by public health decision makers for subsequent COVID-19 vaccine introduction. From our findings, countries and

continents are encouraged to develop their own vaccine against COVID-19 as most participants are more comfortable taking vaccines manufactured in their countries or continents.

Our review has as limitation the fact that we found very few studies which used the DCE as tool for appraising COVID-19 vaccine preferences limiting the scope of our review. It would have been good to have a study on COVID-19 vaccine preferences in Africa, being the continent, which seems to have the highest hesitancy but we could not find any.

The strength of this review is it covers participants from four continents and over 22 000 people so it gives a good picture of COVID-19 vaccine preferences over the world, it brings to light all the factors for COVID-19 vaccine preferences using DCE. This will inform policy makers on better ways to introduce the Covid-19 vaccine to the World in view of better controlling the pandemic.

Conclusion

In conclusion our results suggest that vaccine efficacy, risk of side effects of vaccine, duration of immunity provided and the number of doses are the main factors that influence COVID-19 vaccine uptake. This should be taken into consideration by vaccine manufacturers for better introduction of the vaccine throughout the world.

Authors' contributions

(I) Conception and design: A Amani; (II) Administrative support: A Amani; (III) Collection and analysis of data: S Kenmoe, A. Amani; (IV) Data interpretation and discussion: A Nouko, S Kenmoe A. Amani; (V) Manuscript writing: All authors; (VI) Final approval of manuscript: A Amani, S Kenmoe.

Funding statement

There was no funding for this research.

Competing interest statement

The authors declare no competing interest.

References

- 1. Liu, T., et al., A Comparison of Vaccine Hesitancy of COVID-19 Vaccination in China and the United States. Vaccines, 2021. 9(6).
- 2. Who, WHO Coronavirus (COVID-19) Dashboard. 2021.
- Cheung, E., What does a 'third wave' of Covid-19 infections mean for life in Hong Kong? South China Morning Post, 2020.
- Craig, B.M., United States COVID-19 Vaccination Preferences (CVP): 2020 Hindsight. Patient, 2021. 14(3): p. 309-318.
- Garcia, L.Y. and A.A. Cerda, Contingent assessment of the COVID-19 vaccine. Vaccine, 2020. 38(34): p. 5424-5429.
- Kreps, S.E. and D.L. Kriner, Factors influencing Covid-19 vaccine acceptance across subgroups in the United States: Evidence from a conjoint experiment. Vaccine, 2021. 39(24): p. 3250-3258.
- Leng, A., et al., Individual preferences for COVID-19 vaccination in China. Vaccine, 2021. 39(2): p. 247-254.
- Mello, M.M., R.D. Silverman, and S.B. Omer, Ensuring Uptake of Vaccines against SARS-CoV-2. N Engl J Med, 2020. 383(14): p. 1296-1299.
- Schwarzinger, M., et al., COVID-19 vaccine hesitancy in a representative working-age population in France: a survey experiment based on vaccine characteristics. The Lancet Public Health, 2021. 6(4): p. e210-e221.

- de Bekker-Grob, E.W., et al., The impact of vaccination and patient characteristics on influenza vaccination uptake of elderly people: A discrete choice experiment. Vaccine, 2018. 36(11): p. 1467-1476.
- Dong, D., et al., Public preference for COVID-19 vaccines in China: A discrete choice experiment. Health Expect, 2020. 23(6): p. 1543-1578.
- 12. Kreps, S., et al., Factors Associated With US Adults' Likelihood of Accepting COVID-19 Vaccination. JAMA Netw Open, 2020. 3(10): p. e2025594.
- McPhedran, R. and B. Toombs, Efficacy or delivery? An online Discrete Choice Experiment to explore preferences for COVID-19 vaccines in the UK. Econ Lett, 2021. 200: p. 109747.
- Genie, M.G., et al., Understanding public preferences and trade-offs for government responses during a pandemic: a protocol for a discrete choice experiment in the UK.
 BMJ open, 2020. 10(11): p. e043477-e043477.
- 15. Moher D, L.A., Tetzlaff J, Altman DG, Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 6.
- Motta, M., Can a COVID-19 vaccine live up to Americans ' expectations? A conjoint analysis of how vaccine characteristics influence vaccination intentions. Social Science & Medicine, 2021. 272: p. 13642-13642.
- Romo, M.L., et al., Patterns of SARS-CoV-2 testing preferences in a national cohort in the United States. medRxiv, 2020.
- Díaz Luévano, C., et al., Quantifying healthcare and welfare sector workers' preferences around COVID-19 vaccination: a cross-sectional, single-profile discrete-choice experiment in France. BMJ Open, 2021. 11(10): p. e055148.
- Eshun-Wilson, I., et al., Preferences for COVID-19 vaccine distribution strategies in the US: A discrete choice survey. PLoS One, 2021. 16(8): p. e0256394.

- Huang, W., et al., COVID-19 vaccine coverage, concerns, and preferences among Chinese ICU clinicians: a nationwide online survey. Expert Rev Vaccines, 2021.
 20(10): p. 1361-1367.
- 21. Robertson, M.M., et al., Cohort profile: a national, community-based prospective cohort study of SARS-CoV-2 pandemic outcomes in the USA-the CHASING COVID Cohort study. BMJ open, 2021. 11(9): p. e048778.
- 22. Wang, J., et al., Would COVID-19 vaccination willingness increase if mobile technologies prohibit unvaccinated individuals from public spaces? A nationwide discrete choice experiment from China. Vaccine, 2021.
- Lack A, Hiligsmann M, Bloem P, et al. Parent, provider and vaccinee preferences for HPV vaccination: A systematic review of discrete choice experiments. Vaccine 2020;38:7226–38. doi:10.1016/j.vaccine.2020.08.078.
- Michaels-Igbokwe, C., S. MacDonald, and G.R. Currie, Individual Preferences for Child and Adolescent Vaccine Attributes: A Systematic Review of the Stated Preference Literature. Patient, 2017. 10(6): p. 687-700
- 25. Diks ME, Hiligsmann M, van der Putten IM. Vaccine preferences driving vaccinedecision making of different target groups: a systematic review of choice-based experiments. BMC Infect Dis 2021;21:879. doi:10.1186/s12879-021-06398-9
- Adams, J., et al., Acceptability of Parental Financial Incentives and Quasi-Mandatory Interventions for Preschool Vaccinations: Triangulation of Findings from Three Linked Studies. PLoS One, 2016. 11(6): p. e0156843.
- 27. Adams, J., et al., Effectiveness and acceptability of parental financial incentives and quasi-mandatory schemes for increasing uptake of vaccinations in preschool children:

systematic review, qualitative study and discrete choice experiment. Health Technol

Assess, 2015. 19(94): p. 1-176